Hikma delivers strong H1 performance and raises Generics guidance Growth in all three businesses and across all geographies

Community
By:
On:

Hikma Pharmaceuticals PLC and its subsidiaries (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, report its interim results for the six months ended 30 June 2023. During the first half of 2023, core group revenue grew 18% to $1.427 billion (compared to H1 2022: $1.213 billion), driven by a strong performanceContinue Reading